SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock. This program builds on United Therapeutics’ planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024..

马里兰州银泉市和北卡罗来纳州三角研究园（BUSINESS WIRE）--公共利益公司联合治疗公司（Nasdaq:UTHR）今天宣布，其董事会已授权该公司购买高达10亿美元的联合治疗公司普通股。该计划的基础是联合治疗公司计划在2024年偿还其循环贷款的4亿美元，其中1亿美元在2024年第一季度偿还。。

To enact the program, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase $1 billion of the company’s common stock.

为了实施该计划，联合治疗公司（United Therapeutics）今天将与花旗银行（Citibank，N.A.）（Citi）签订加速股份回购（ASR）协议，回购该公司10亿美元的普通股。

“We’re in a unique position with a solid, growing, and profitable cash-generating business along with the potential to revolutionize the way end-stage organ disease is treated through an unlimited supply of tolerable, transplantable organs,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

联合治疗公司（United Therapeutics）主席兼首席执行官马丁·罗斯布拉特（Martine Rothblatt）博士说：“我们拥有一项稳定、不断增长、盈利的现金产生业务，并且有可能通过无限量供应可耐受、可移植的器官来彻底改变终末期器官疾病的治疗方式，因此我们处于独特的地位。”。

“Having learned a great deal through the construction and commissioning of the world’s first clinical-scale designated pathogen-free facility to support our xenotransplantation efforts, we are confident in our ability to fund future facilities while balancing prudent capital allocation for all of our stakeholders.

“通过建造和调试世界上第一个临床规模的指定无病原体设施来支持我们的异种移植工作，我们学到了很多东西，我们有信心为未来的设施提供资金，同时为所有利益相关者平衡审慎的资本分配。

The current valuation of United Therapeutics’ stock makes repurchases of UTHR shares a solid investment and represents a chance to enhance long-term shareholder value.”.

目前对联合治疗公司股票的估值使回购UTHR股票成为一项可靠的投资，并为提高长期股东价值提供了机会。”。

Under the terms of the ASR agreement, on March 27, 2024, United Therapeutics will make an aggregate upfront payment of $1 billion to Citi and will receive an initial delivery of shares representing approximately 80% of the total shares that would be repurchased under the ASR agreement measured based on the closing stock price of UTHR’s common stock on March 25, 2024.

根据ASR协议的条款，联合治疗将于2024年3月27日向花旗支付总额为10亿美元的预付款，并将收到首次交付的股份，约占根据ASR协议回购的总股份的80%，该股份将根据2024年3月25日UTHR普通股的收盘价进行衡量。

The final number of shares that United Therapeutics will ultimately repurchase pursuant to the ASR agreement will be based on the average of the daily volume-weighted average price per share of United Therapeutics’ common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement.

根据ASR协议，United Therapeutics最终将回购的股份最终数量将基于ASR期间United Therapeutics普通股每日成交量加权平均价格的平均值，减去折扣，并根据ASR协议的条款和条件进行调整。

At final settlement of the ASR agreement, United Therapeutics may be entitled to receive additional shares of United Therapeutics’ common stock, or, under certain limited circumstances, be required to make cash payment to Citi or, if United Therapeutics elects, deliver shares to Citi. The final settlement of the ASR is expected to be completed in the second quarter of 2024 with respect to $300 million of the ASR and in the third quarter of 2024 with respect to $700 million of the ASR.

在ASR协议最终结算时，联合疗法可能有权获得联合疗法普通股的额外股份，或者在某些有限的情况下，被要求向花旗支付现金，或者如果联合疗法选择向花旗交付股份。ASR的最终结算预计将于2024年第二季度完成，涉及ASR的3亿美元，并于2024年第三季度完成，涉及ASR的7亿美元。

As of February 14, 2024, United Therapeutics had approximately 47.1 million shares outstanding..

截至2024年2月14日，联合疗法拥有约4710万股流通股。。

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

本新闻稿不构成出售要约或招揽购买任何证券的要约，也不构成在该等要约、招揽或出售不合法的任何司法管辖区内的要约、招揽或出售。

United Therapeutics: Enabling Inspiration

联合疗法：激发灵感

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

在联合治疗公司，我们的愿景和使命是一体的。我们利用我们的热情、创造力和毅力来创新，以满足患者未满足的医疗需求，并使其他利益相关者受益。我们大胆而非传统。我们玩得很开心；我们做得很好。我们是第一家以公益公司（PBC）形式上市的生物技术或制药公司。

Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs..

我们的公益目的是通过（a）开发新型药物疗法为患者提供更光明的未来；（b）扩大可移植器官可用性的技术。。

You can learn more about what it means to be a PBC here: unither.com/pbc.

你可以在这里了解更多关于PBC意味着什么：unither.com/PBC。

Forward-Looking Statements

前瞻性声明

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our confidence in our near-term prospects; the amount of our planned paydown of our revolving credit facility; the growth of our business; our potential to revolutionize the way end-stage organ disease is treated; our ability to fund future facilities; the benefits of the share repurchase to shareholders; our plan to enter into an ASR agreement; the number of shares to be repurchased under the ASR agreement; the timing and manner of the final settlement under the ASR agreement; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

本新闻稿中包含的非历史性声明是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。前瞻性声明包括与我们对近期前景的信心有关的声明；我们计划偿还的循环信贷额度；我们业务的增长；我们有可能彻底改变终末期器官疾病的治疗方式；我们为未来设施提供资金的能力；回购股份给股东带来的利益；我们签订ASR协议的计划；根据ASR协议回购的股份数量；ASR协议下最终结算的时间和方式；我们的目标是创新以满足患者未满足的医疗需求，并使我们的其他利益相关者受益，进一步实现我们的公共利益目标，即开发新的药物疗法和技术，扩大可移植器官的可用性。

These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

这些前瞻性陈述受到某些风险和不确定性的影响，例如我们向美国证券交易委员会提交的定期报告中所述的风险和不确定性，这可能导致实际结果与预期结果产生重大差异。因此，此类前瞻性声明符合我们向证券交易委员会提交的定期报告和文件中规定的警示声明、警示语言和风险因素，包括我们最近的10-K表年度报告、10-Q表季度报告和8-K表当前报告。

We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 25,.

我们要求保护1995年《私人证券诉讼改革法案》中所载的前瞻性声明的安全港。我们将于3月25日提供此信息，。